Laboratoire de Pharmaco-Chimie Radicalaire, Universités d'Aix-Marseille I, Marseille, France.
J Pharm Pharm Sci. 2012;15(1):124-40. doi: 10.18433/j39k5h.
Since 1976, fibrin glues have been attracting medical interest, spreading from their initial use as a hemostatic agent in cardiovascular surgery to other fields of surgery. Studies have compared the efficacy of fibrin glues vs sutures in surgery. However, few comparisons have been made of the efficacy and safety of the different fibrin glues commercially available. Recently, fibrin glues have been tested as a scaffold delivery system for various substances inside the body (drugs, growth factors, stem cells). The infectious risk (viruses, new germs) of this blood-derived product was also studied in assays on viral inactivation methods. The development of autologous fibrin glues offers a solution to the problem of infectious risk. This review examines the current state of knowledge on the efficacy, safety and future potential of fibrin glues.
自 1976 年以来,纤维蛋白胶一直受到医学关注,其应用范围从最初在心血管手术中的止血剂扩展到其他外科领域。已有研究比较了纤维蛋白胶与缝线在手术中的疗效。然而,对于市售的不同纤维蛋白胶的疗效和安全性,很少有比较。最近,纤维蛋白胶已被测试作为体内各种物质(药物、生长因子、干细胞)的支架输送系统。该血液衍生产品的感染风险(病毒、新病菌)也通过病毒灭活方法的检测进行了研究。自体纤维蛋白胶的开发为解决感染风险问题提供了一种解决方案。本文综述了纤维蛋白胶的疗效、安全性和未来潜力的现有知识状况。